Increase in the proliferative capacity of human myoblasts by using the T antigen under the vimentin promoter control

Deschênes, Isabelle; Chahine, Mohamed; Tremblay, Jacques P.; Paulin, Denise; Puymirat, Jack

doi:10.1002/(sici)1097-4598(199704)20:4<437::aid-mus6>3.0.co;2-b

Cited by 13 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As expected the majority of the identified proteins are cytosolic, mitochondrial or membrane proteins. On the 13th day of differentiation some proteins known to be highly expressed during myoblast differentiation were identified (myosin, creatine-kinase, calpo-nin-3, muscle-specific beta enolase, [18]), and others known for their low expression in myotubes disappeared (alphaactinin 4; vimentin [19]). Moreover, in complete agreement with the exit of cells from the cell cycle during myoblast differentiation, expression of a subset of proteins involved in cellular proliferation (c-Crk1; DNA replication licensing factor MCM7; mitogen-activated protein kinase 1) were con-siderably decreased in the 13th day myotube cultures.…”

Section: ---: Binding;mentioning

confidence: 99%

Proteome analysis of differentiating human myoblasts by dialysis‐assisted two‐dimensional gel electrophoresis (DAGE)

et al. 2008

View full text Add to dashboard Cite

In the present study, modifications in cytosolic expressed proteins during human myoblast differentiation were studied by dialysis-assisted 2-DE (DAGE, [1]). About 1000 spots were analysed on the 5th and 13th day of differentiation with a dynamic range of protein expression exceeding 1000-fold. During myogenic differentiation, the number of nonmatching spots as well as the extent of quantitative differences between matched spots significantly increased. Over one hundred differentially expressed spots were excised and identified by MALDI-TOF MS. The differentiation-associated expression pattern of eight proteins was validated by Western blot analysis. Differential expression of several proteins was demonstrated for the first time in human myotubes. Interestingly, Ingenuity pathway analysis grouped 30 of these proteins into two overlapping networks containing as principal nodes IGF-1 and tumour necrosis factor, two proteins known to play a crucial role in cytogenesis. Our results illustrate the large rearrangement of the proteome during the differentiation of human myoblasts and provide evidence for new partners involved in this complex process.

show abstract

Section: ---: Binding;mentioning

confidence: 99%

Proteome analysis of differentiating human myoblasts by dialysis‐assisted two‐dimensional gel electrophoresis (DAGE)

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Large T antigen, from SV40, has been used by several groups, including ours, but its expression only extends the lifespan by 20–25 divisions (Mouly et al. 1996, Deschênes et al. 1997), and in addition it has deleterious effects on muscle specific gene expression of human satellite cells (Mouly et al.…”

Section: Isolation In Vitro and Proliferative Capacity Of Human Satelmentioning

confidence: 99%

“…Another approach is to extend the proliferative capacity of the satellite cells by genetic modification. Large T antigen, from SV40, has been used by several groups, including ours, but its expression only extends the lifespan by 20-25 divisions (Mouly et al 1996, Deschênes et al 1997, and in addition it has deleterious effects on muscle specific gene expression of human satellite cells (Mouly et al 1996). An alternative approach is provided by the recent cloning of the human gene coding for telomerase, an enzyme that functions to elongate telomeres and thus extend proliferative capacity.…”

Section: Introductionmentioning

confidence: 99%

The mitotic clock in skeletal muscle regeneration, disease and cell mediated gene therapy

Mouly

Aamiri

Bigot

et al. 2005

Acta Physiologica Scandinavica

View full text Add to dashboard Cite

The regenerative capacity of skeletal muscle will depend on the number of available satellite cells and their proliferative capacity. We have measured both parameters in ageing, and have shown that although the proliferative capacity of satellite cells is decreasing during muscle growth, it then stabilizes in the adult, whereas the number of satellite cells decreases during ageing. We have also developed a model to evaluate the regenerative capacity of human satellite cells by implantation into regenerating muscles of immunodeficient mice. Using telomere measurements, we have shown that the proliferative capacity of satellite cells is dramatically decreased in muscle dystrophies, thus hampering the possibilities of autologous cell therapy. Immortalization by telomerase was unsuccessful, and we currently investigate the factors involved in cell cycle exits in human myoblasts. We have also observed that insulin-like growth factor-1 (IGF-1), a factor known to provoke hypertrophy, does not increase the proliferative potential of satellite cells, which suggests that hypertrophy is provoked by increasing the number of satellite cells engaged in differentiation, thus possibly decreasing the compartment of reserve cells. We conclude that autologous cell therapy can be applied to specific targets when there is a source of satellite cells which is not yet exhausted. This is the case of Oculo-Pharyngeal Muscular Dystrophy (OPMD), a late onset muscular dystrophy, and we participate to a clinical trial using autologous satellite cells isolated from muscles spared by the disease.

show abstract

Progress in myoblast transplantation: a potential treatment of dystrophies

Skuk

Tremblay

2000

Microsc. Res. Tech.

View full text Add to dashboard Cite

Myoblast transplantation (MT) consists of injecting normal or genetically modified myogenic cells into muscles, where they are expected to fuse and form mature fibers. As an experimental approach to treat severe genetic muscle diseases, MT was tested in dystrophic patients at the beginning of the 1990s. Although these early clinical trials were unsuccessful, MT has progressed through the research on animal models. Many factors that may condition the success of MT were identified in the last years. The present review updates our knowledge on MT and describes the different problems that have limited its success. Factors that were first underestimated, like the specific immune response after MT, are presently well characterized. Destruction of the hybrid fibers by activated T‐lymphocytes and production of antibodies against the transplanted myoblasts take place after MT and are responsible for the graft rejection. The choice of the immunosuppression seems to be very important, and FK506 is the best agent known to allow the best results after MT. Under FK506 immunosuppression, very efficient MT were obtained both in mice and monkeys. Moreover, in dystrophic mice it was demonstrated that MT ameliorates some phenotypical characteristics of the disease. The improvement of the survival of the transplanted cells and the increase of their migration into the injected tissue are presently under investigation. Some of the present research is directed also to bypass the immunosuppression by using the patient's own cells for MT. In this sense, efforts are conducted to introduce the normal gene into the patient's myoblasts before MT and to improve the ability of these cells to proliferate in vitro. Micros. Res. Tech. 48:213–222, 2000. © 2000 Wiley‐Liss, Inc.

show abstract

Increase in the proliferative capacity of human myoblasts by using the T antigen under the vimentin promoter control

Cited by 13 publications

References 23 publications

Proteome analysis of differentiating human myoblasts by dialysis‐assisted two‐dimensional gel electrophoresis (DAGE)

Proteome analysis of differentiating human myoblasts by dialysis‐assisted two‐dimensional gel electrophoresis (DAGE)

The mitotic clock in skeletal muscle regeneration, disease and cell mediated gene therapy

Progress in myoblast transplantation: a potential treatment of dystrophies

Contact Info

Product

Resources

About